Elicio Therapeutics Inc (ELTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.90-2.06%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Elicio Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	0
EPS	—	-0.46
R&D	$6.8M	—
FY 2026 · Annual
Revenue	—	20M
EPS	—	-1.882
FY 2027 · Annual
Revenue	—	0
EPS	—	-1.691

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Extend cash runway into Q4 2026	Elicio aims to extend cash into Q4 2026.	Intact	Cash runway falls short of Q4 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage losses and improve EPS trajectory	A supporting condition in Elicio Therapeutics Inc's published investment case. The stated target is EPS loss narrows or stabilizes by FY27.	Improving	EPS loss worsens beyond -$2.43 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Conduct AMPLIFY-7P Phase 2 DFS analysis	A primary condition in Elicio Therapeutics Inc's published investment case. The stated target is Complete Phase 2 DFS analysis in H1 2026.	Improving	Phase 2 DFS analysis delayed beyond H1 2026 or negative results	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	2 / 0
2026-07-30	Unavailable	Unavailable	2 / 0
2026-07-31	Unavailable	Unavailable	2 / 0
2026-08-01	Unavailable	Unavailable	2 / 0
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	2 / 0
2026-08-05	Unavailable	Unavailable	3 / 3
2026-08-06	Unavailable	Unavailable	2 / 0
2026-08-07	Unavailable	Unavailable	2 / 0
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-11	Unavailable	Unavailable	2 / 0
2026-08-12	Unavailable	Unavailable	2 / 0
2026-08-13	Unavailable	Unavailable	3 / 3
2026-08-14	Unavailable	Unavailable	2 / 0
2026-08-15	Unavailable	Unavailable	2 / 0
2026-08-16	Unavailable	Unavailable	2 / 0
2026-08-17	Unavailable	Unavailable	2 / 0
2026-08-18	Unavailable	Unavailable	2 / 0
2026-08-19	Unavailable	Unavailable	2 / 0
2026-08-20	Unavailable	Unavailable	3 / 0
2026-08-21	Unavailable	Unavailable	3 / 0
2026-08-22	Unavailable	Unavailable	3 / 0
2026-08-23	Unavailable	Unavailable	3 / 0
2026-08-24	Unavailable	Unavailable	3 / 0
2026-08-25	Unavailable	Unavailable	3 / 0
2026-08-26	Unavailable	Unavailable	3 / 0
2026-08-27	Unavailable	Unavailable	3 / 0
2026-08-28	Unavailable	Unavailable	3 / 0
2026-08-29	Unavailable	Unavailable	3 / 0
2026-08-30	Unavailable	Unavailable	3 / 0
2026-08-31	Unavailable	Unavailable	3 / 0
2026-09-01	Unavailable	Unavailable	3 / 0
2026-09-02	Unavailable	Unavailable	3 / 0
2026-09-03	Unavailable	Unavailable	3 / 0
2026-09-04	Unavailable	Unavailable	3 / 0
2026-09-05	Unavailable	Unavailable	3 / 0
2026-09-06	Unavailable	Unavailable	3 / 0
2026-09-07	Unavailable	Unavailable	3 / 0
2026-09-08	Unavailable	Unavailable	3 / 0
2026-09-09	Unavailable	Unavailable	3 / 0
2026-09-10	Unavailable	Unavailable	3 / 0
2026-09-11	Unavailable	Unavailable	3 / 0
2026-09-12	Unavailable	Unavailable	3 / 0
2026-09-13	Unavailable	Unavailable	3 / 0
2026-09-14	Unavailable	Unavailable	3 / 0
2026-09-15	Unavailable	Unavailable	3 / 0
2026-09-16	Unavailable	Unavailable	3 / 0
2026-09-17	Unavailable	Unavailable	3 / 0
2026-09-18	Unavailable	Unavailable	3 / 0
2026-09-19	Unavailable	Unavailable	3 / 0
2026-09-20	Unavailable	Unavailable	3 / 0
2026-09-21	Unavailable	Unavailable	3 / 0
2026-09-22	Unavailable	Unavailable	3 / 0
2026-09-23	Unavailable	Unavailable	3 / 0
2026-09-24	Unavailable	Unavailable	3 / 0
2026-09-25	Unavailable	Unavailable	3 / 0
2026-09-26	Unavailable	Unavailable	3 / 0
2026-09-27	Unavailable	Unavailable	3 / 0
2026-09-28	Unavailable	Unavailable	3 / 0
2026-09-29	Unavailable	Unavailable	3 / 0
2026-09-30	Unavailable	Unavailable	3 / 0
2026-10-01	Unavailable	Unavailable	3 / 0
2026-10-02	Unavailable	Unavailable	3 / 0
2026-10-03	Unavailable	Unavailable	3 / 0
2026-10-04	Unavailable	Unavailable	3 / 0
2026-10-05	Unavailable	Unavailable	3 / 0
2026-10-06	Unavailable	Unavailable	3 / 0
2026-10-07	Unavailable	Unavailable	3 / 0
2026-10-08	Unavailable	Unavailable	3 / 0
2026-10-09	Unavailable	Unavailable	3 / 0
2026-10-10	Unavailable	Unavailable	3 / 0
2026-10-11	Unavailable	Unavailable	3 / 0
2026-10-12	Unavailable	Unavailable	3 / 0
2026-10-13	Unavailable	Unavailable	3 / 0
2026-10-14	Unavailable	Unavailable	3 / 0
2026-10-15	Unavailable	Unavailable	3 / 0
2026-10-16	Unavailable	Unavailable	3 / 0
2026-10-17	Unavailable	Unavailable	3 / 0
2026-10-18	Unavailable	Unavailable	3 / 0
2026-10-19	Unavailable	Unavailable	3 / 0
2026-10-20	Unavailable	Unavailable	3 / 0
2026-10-21	Unavailable	Unavailable	3 / 0
2026-10-22	Unavailable	Unavailable	3 / 0
2026-10-23	Unavailable	Unavailable	3 / 0
2026-10-24	Unavailable	Unavailable	3 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	0
2026-06-01	3	1
2026-07-01	3	1
2026-08-01	3	1
2026-09-01	3	1
2026-10-01	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Extend cash runway into Q4 2026Direct metric needs a verified mapping
Manage losses and improve EPS trajectoryDirect metric needs a verified mapping
Conduct AMPLIFY-7P Phase 2 DFS analysisDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-89.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Elicio Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ELTX is a speculative, loss-making biotechnology company whose prospects depend on clinical-trial progress rather than established earnings. The thesis is on watch: management is advancing a revised development plan, but recent financial performance is weak and overall risk is high.

What's priced into Elicio Therapeutics Inc

The valuation evidence suggests ELTX is cheap versus peers, but confidence in that comparison is low and it does not establish that the shares are undervalued. The evidence does not specify what clinical or financial expectations the market already assumes; low fragility indicators provide little additional insight into that expectations gap.

What the fundamentals likely do

Near term, results may remain uneven: ELTX reported an earnings miss in May and a beat in August, while the stated risk of a next-quarter miss is elevated. Over the multi-year view, the Phase 2 trial missed its main endpoint, though a post-hoc subgroup showed a favorable signal; management is refining the Phase 3 plan and has extended projected cash runway into Q1 2027 through financing and cash management.

What Elicio Therapeutics Inc hinges on

The main swing factor is whether the subgroup signal supports a clear Phase 3 design and is confirmed in further testing. Near term, guidance cuts or continued weakening in jobs data could weigh on sentiment, while strong results and higher guidance from Healthcare bellwethers could support the sector backdrop.